(AORT) Artivion - Overview
Stock: BioGlue, Stent Grafts, Heart Valves, Vascular Grafts, Hemostat
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 36.0% |
| Relative Tail Risk | -10.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.67 |
| Alpha | 12.75 |
| Character TTM | |
|---|---|
| Beta | 0.697 |
| Beta Downside | 0.521 |
| Drawdowns 3y | |
|---|---|
| Max DD | 30.00% |
| CAGR/Max DD | 1.47 |
Description: AORT Artivion January 15, 2026
Artivion, Inc. (AORT) is a global medical-device and tissue-technology company that markets a diversified portfolio ranging from the BioGlue surgical sealant and bovine pericardial patches to a suite of endovascular stent-graft systems (e.g., E-vita Open NEO, E-nside, E-ventus BX) and the On-X mechanical heart-valve line. The firm also provides ancillary services such as tissue preservation, carbon-coating, and custom engineering solutions for aortic and peripheral vascular disease, serving cardiac, vascular, thoracic and general surgeons worldwide.
Key recent metrics: Artivion reported FY 2023 revenue of roughly **$420 million**, a **~9% year-over-year increase**, driven primarily by growth in its endovascular stent-graft segment and expanding adoption of the On-X valve platform. The company’s **gross margin** held steady near **68%**, reflecting the high-value nature of its specialty products. Sector-wide, U.S. spending on minimally invasive cardiovascular procedures is projected to rise **5-6% annually** through 2028, while the aging population (≥65 years) is expected to boost demand for aortic-repair and valve-replacement therapies-both core growth engines for Artivion.
For a deeper quantitative assessment, you might explore ValueRay’s analyst tools to see how these trends translate into valuation scenarios.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -9.14m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.44 > 1.0 |
| NWC/Revenue: 46.84% < 20% (prev 35.11%; Δ 11.73% < -1%) |
| CFO/TA 0.03 > 3% & CFO 28.7m > Net Income -9.14m |
| Net Debt (188.6m) to EBITDA (45.4m): 4.15 < 3 |
| Current Ratio: 3.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (48.8m) vs 12m ago 16.56% < -2% |
| Gross Margin: 64.50% > 18% (prev 0.65%; Δ 6385 % > 0.5%) |
| Asset Turnover: 50.90% > 50% (prev 47.92%; Δ 2.97% > 0%) |
| Interest Coverage Ratio: 0.73 > 6 (EBITDA TTM 45.4m / Interest Expense TTM 30.8m) |
Altman Z'' 1.35
| A: 0.23 (Total Current Assets 283.8m - Total Current Liabilities 85.8m) / Total Assets 857.7m |
| B: -0.06 (Retained Earnings -53.9m / Total Assets 857.7m) |
| C: 0.03 (EBIT TTM 22.4m / Avg Total Assets 830.4m) |
| D: -0.13 (Book Value of Equity -55.7m / Total Liabilities 419.0m) |
| Altman-Z'' Score: 1.35 = BB |
Beneish M -2.85
| DSRI: 1.14 (Receivables 97.4m/78.0m, Revenue 422.6m/384.9m) |
| GMI: 1.00 (GM 64.50% / 64.53%) |
| AQI: 1.06 (AQ_t 0.58 / AQ_t-1 0.54) |
| SGI: 1.10 (Revenue 422.6m / 384.9m) |
| TATA: -0.04 (NI -9.14m - CFO 28.7m) / TA 857.7m) |
| Beneish M-Score: -2.85 (Cap -4..+1) = A |
What is the price of AORT shares?
Over the past week, the price has changed by -2.89%, over one month by -12.72%, over three months by -16.65% and over the past year by +26.61%.
Is AORT a buy, sell or hold?
- StrongBuy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AORT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 51.7 | 30.6% |
| Analysts Target Price | 51.7 | 30.6% |
| ValueRay Target Price | 44.4 | 12% |
AORT Fundamental Data Overview February 03, 2026
P/S = 4.57
P/B = 4.365
P/EG = 181.5
Revenue TTM = 422.6m USD
EBIT TTM = 22.4m USD
EBITDA TTM = 45.4m USD
Long Term Debt = 214.9m USD (from longTermDebt, last quarter)
Short Term Debt = 5.80m USD (from shortTermDebt, last quarter)
Debt = 262.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 188.6m USD (from netDebt column, last quarter)
Enterprise Value = 2.12b USD (1.93b + Debt 262.0m - CCE 73.4m)
Interest Coverage Ratio = 0.73 (Ebit TTM 22.4m / Interest Expense TTM 30.8m)
EV/FCF = 134.6x (Enterprise Value 2.12b / FCF TTM 15.8m)
FCF Yield = 0.74% (FCF TTM 15.8m / Enterprise Value 2.12b)
FCF Margin = 3.73% (FCF TTM 15.8m / Revenue TTM 422.6m)
Net Margin = -2.16% (Net Income TTM -9.14m / Revenue TTM 422.6m)
Gross Margin = 64.50% ((Revenue TTM 422.6m - Cost of Revenue TTM 150.1m) / Revenue TTM)
Gross Margin QoQ = 65.61% (prev 64.72%)
Tobins Q-Ratio = 2.47 (Enterprise Value 2.12b / Total Assets 857.7m)
Interest Expense / Debt = 2.34% (Interest Expense 6.12m / Debt 262.0m)
Taxrate = 7.85% (554.0k / 7.06m)
NOPAT = 20.7m (EBIT 22.4m * (1 - 7.85%))
Current Ratio = 3.31 (Total Current Assets 283.8m / Total Current Liabilities 85.8m)
Debt / Equity = 0.60 (Debt 262.0m / totalStockholderEquity, last quarter 438.7m)
Debt / EBITDA = 4.15 (Net Debt 188.6m / EBITDA 45.4m)
Debt / FCF = 11.97 (Net Debt 188.6m / FCF TTM 15.8m)
Total Stockholder Equity = 357.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.10% (Net Income -9.14m / Total Assets 857.7m)
RoE = -2.56% (Net Income TTM -9.14m / Total Stockholder Equity 357.3m)
RoCE = 3.92% (EBIT 22.4m / Capital Employed (Equity 357.3m + L.T.Debt 214.9m))
RoIC = 3.32% (NOPAT 20.7m / Invested Capital 622.2m)
WACC = 7.72% (E(1.93b)/V(2.19b) * Re(8.48%) + D(262.0m)/V(2.19b) * Rd(2.34%) * (1-Tc(0.08)))
Discount Rate = 8.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.21%
[DCF Debug] Terminal Value 71.51% ; FCFF base≈13.9m ; Y1≈9.16m ; Y5≈4.18m
Fair Price DCF = N/A (negative equity: EV 85.9m - Net Debt 188.6m = -102.7m; debt exceeds intrinsic value)
EPS Correlation: 13.42 | EPS CAGR: -1.92% | SUE: -0.39 | # QB: 0
Revenue Correlation: 95.54 | Revenue CAGR: 9.97% | SUE: 0.92 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.12 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=0.84 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+33.1% | Growth Revenue=+11.0%